Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer Society explains Italy’s progress with next-generation sequencing (NGS) and the creation of molecular tumour boards. He also discusses the need for partnerships between institutions and pharma companies and predicts the positive impact of precision medicine on the Italian system.
Scientific organizations are all aligned on the message that we need to implement NGS, but we need national guidelines.
